StemRIM Inc. (4599) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-09-25 | — | Patent Registration in South Korea for Redasemtide in Cartilage Disorders | |
| 2026-09-25 | — | Nomination of Director Candidates, Audit & Supervisory Board Member and Substitute Audit & Supervisory Board Member Candidates | |
| 2026-09-25 | — | Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators | |
| 2026-09-10 | — | StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees | |
| 2026-09-10 | — | StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors | |
| 2026-09-09 | — | StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees | |
| 2026-09-09 | — | StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors | |
| 2026-09-09 | Earnings Release | Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2026 [Japanese GAAP] | |
| 2026-08-03 | — | StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea | |
| 2026-07-22 | — | StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders | |
| 2026-07-13 | — | StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.